Testosterone Enanthate and Rivaroxaban Interaction: What Patients and Clinicians Need to Know

What does the testosterone enanthate label say about anticoagulants?

Under Drug Interactions, the label carries this entry: 'Anticoagulants, oral – C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirement. Patients receiving oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.' [1]

Two details matter. The example the label names is methandrostenolone, and the entry does not say whether it applies to testosterone enanthate itself. The monitoring statement names no specific test, no target and no schedule.

The label's hematologic adverse reaction list is more concrete: 'Suppression of clotting factors II, V, VII, and X; bleeding in patients on concomitant anticoagulant therapy; polycythemia' [1]. Its warnings also report venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, in patients using testosterone products such as testosterone enanthate injection, and say to evaluate symptoms of limb pain, edema, warmth and erythema for DVT and acute shortness of breath for PE [1].

Does that warning cover rivaroxaban?

Rivaroxaban is an oral, direct factor Xa inhibitor that targets free and clot-bound factor Xa and factor Xa in the prothrombinase complex [2]. It is taken by mouth and it is an anticoagulant, so it sits inside the class the enanthate label names, even though the label does not name the drug.

The Xarelto label says that monitoring its anticoagulant effect with PT, INR, aPTT or anti-factor Xa tests is not recommended. The enanthate label's entry does not specify what the close monitoring should consist of.

Bleeding numbers from the rivaroxaban trials

These figures come from large trials in atrial fibrillation and vascular disease populations, not from men taking testosterone. ROCKET AF randomized 14,264 patients with non-valvular atrial fibrillation to rivaroxaban 20 mg daily or dose-adjusted warfarin. Stroke or systemic embolism occurred at 1.7% versus 2.2% per year, and major plus nonmajor clinically relevant bleeding occurred in 14.9% versus 14.5% per year (hazard ratio 1.03, 95% CI 0.96 to 1.11) [4].

In COMPASS, 27,395 people with stable atherosclerotic vascular disease received rivaroxaban 2.5 mg twice daily plus aspirin 100 mg, rivaroxaban 5 mg twice daily, or aspirin alone. The composite of cardiovascular death, stroke or myocardial infarction occurred in 4.1% with rivaroxaban plus aspirin versus 5.4% with aspirin alone, while major bleeding occurred in 3.1% versus 1.9% (hazard ratio 1.70, 95% CI 1.40 to 2.05) [5].

Is there a pharmacokinetic interaction?

Rivaroxaban is absorbed rapidly, with peak plasma concentrations 2 to 4 hours after a tablet, and its elimination half-life is 5 to 9 hours in healthy young subjects and 11 to 13 hours in elderly subjects [2]. It does not inhibit cytochrome P450 enzymes or known drug transporter systems, and because it has multiple elimination pathways it has no clinically relevant interactions with most commonly prescribed medications [2]. Its pharmacodynamic effect tracks its plasma concentration closely [2].

The testosterone enanthate label frames its anticoagulant entry around the anticoagulant requirement and clotting factors, not around liver enzymes or plasma levels, and does not describe an enzyme-based interaction [1].

Hematocrit and clotting: what injectable testosterone does

The enanthate label lists polycythemia among hematologic adverse reactions [1]. A network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found that intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% (95% CI 2.9 to 5.1) versus placebo, compared with 3.0% for gel and 1.4% for patch [3].

A retrospective single-center review of 178 hypogonadal men followed for three years reported erythrocytosis, defined there as hematocrit above 50%, in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets. The injection group was younger (mean 42.5 versus about 54 years) with a higher starting hematocrit, and the study was not randomized [6]. Two reviews describe erythrocytosis as well established with testosterone therapy, highest with short-acting injectables, and both note that the link between erythrocytosis and thromboembolic events remains unclear [7][8].